This statistic depicts the total number of annual new HIV infections worldwide from 2000 to 2024. UNAIDS estimated that there were some *** million people worldwide that were newly infected with HIV in 2024. Total number of new HIV infections worldwideHuman immunodeficiency virus (HIV) is a condition that slowly destroys or impairs the body’s immune system. It is a retrovirus that slowly progresses through the various stages of the disease. As HIV reproduces, it mutates its structure, which makes it difficult to treat through drug therapy. Around **** million people were living with HIV worldwide as of 2024 with some **** million people accessing ART treatment. There are various types of ways to treat HIV. Antiviral treatment has been on the decline as combination therapy such as fixed-dose combinations become more popular. New HIV infections worldwide have been on the decline since 2000 from *** million new infections to *** million new infections in 2024. Many new infections occur in developing countries, especially those in low- and middle-income countries in Sub-Saharan Africa. Many of these individuals have no access to drugs or treatment that can make living with HIV more manageable. Children are also susceptible to infection, often from HIV-positive mothers during pregnancy, childbirth, or breastfeeding. There are approximately *** million children living with HIV globally.

The total number of people globally living with HIV has increased from **** million people in 2000 to **** million people in 2024. However, the total number of new HIV infections has decreased from *** million in 2000 to *** million in 2024. It has become easier for those infected with HIV to live longer lives. Death rates for HIV-positive people are decreasing, mostly due to antiretroviral drugs that have turned the infection into a chronic disease. Nevertheless, those with HIV are at a higher risk for conditions such as liver disease, heart disease, and cancer. Medication for HIV has become more widespread and has made HIV a more manageable condition. However, medicine is not widely accessible in the developing world, and treatment is still lacking. In Eswatini, around ** percent of all people between 15 and 49 years are living with HIV, while the percentage is around ** in South Africa. HIV infections are still especially widespread in Eastern and Southern Africa, with **** million people living with the condition in 2024. In the same year, there were around *** million people in Latin America living with HIV.

Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, South Africa, and Lesotho. In 2024, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids, and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased. However, despite being available worldwide, not all adults have access to antiretroviral drugs. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

The average for 2022 based on 135 countries was 1.66 percent. The highest value was in Swaziland: 25.9 percent and the lowest value was in Afghanistan: 0.1 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.

In 2024, in South Africa, there were around 3.1 HIV newly infected persons per every 1,000 inhabitants. This statistic depicts the countries with the highest incidence rates of new HIV infections worldwide as of 2024.

In Italy, the total number of newly diagnosed HIV (human immunodeficiency virus) infections peaked in 2012, when ***** new cases were recorded. Thereafter, the number gradually decreased until 2020, when ***** individuals were newly diagnosed with HIV, to rise again in 2021, 2022, and 2023. This virus is responsible for AIDS (acquired immunodeficiency syndrome), which is a condition that remarkably weakens the immune system, making the contraction of diseases much more likely. HIV incidence worldwide In 2023, roughly **** million people suffered from HIV worldwide. The number of people living with HIV steadily grew from 2000 to 2023. Nonetheless, the number of new HIV infections decreased over time.  HIV epidemiology in Italy In Italy, the regions of Lombardy, Lazio, and Emilia-Romagna were the ones with the highest number of people newly diagnosed with HIV in 2023. The virus was mainly prevalent among males aged 30 to 49 years old during this same period. Indeed, *** men aged between 30 and 39 years, and *** between 40 and 49 years old, were newly diagnosed with HIV.  

According to Cognitive Market Research, the global HIV Diagnostics market size is USD 4158.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 10.90% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 1663.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1247.46 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 956.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031. Latin America had a market share of more than 5% of the global revenue with a market size of USD 207.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 83.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031. Consumables held the highest HIV Diagnostics market revenue share in 2024. Market Dynamics of HIV Diagnostics Market Key Drivers for HIV Diagnostics Market Increasing Prevalence of Sexually Transmitted Disease to Increase the Demand Globally Throughout the many decades of the HIV pandemic, the number of infected individuals is continually rising. The socioeconomic variables driving this continuous increase also suggest that preventative measures have not been successful. Even though many of these infections are preventable, there are an estimated 20 million new cases of STDs in the US each year, and the rate is still rising. Moreover, there are over 1.2 million HIV-positive individuals residing in the United States. Attempts to encourage testing and screening for sexually transmitted infections can ascertain an individual's likelihood of acquiring one and help those who already have one receive treatment, so enhancing their health and lowering the danger of HIV spreading to others. Approximately 38.4 million people worldwide were HIV positive in 2021. Among these, women and girls made up nearly 54%. Rising Initiatives by Global Agencies to Propel Market Growth HIV is among the world's most important public health concerns. As a result, there is a global commitment to stopping new HIV infections and giving everyone on the planet access to HIV therapy. WHO recommends testing for HIV to anyone who might be at risk. The World Bank was a leader in global financing for HIV/AIDS in the early phases of the pandemic and has contributed US$4.6 billion to programs related to the illness since 1989. Because of assistance from the Bank—more precisely, through the International Development Association—for 1,500 counseling and testing centers, about 7 million people have had HIV tests. Restraint Factor for the HIV Diagnostics Market Lack of Healthcare Infrastructure and Awareness to Limit the Sales A proper infrastructure for healthcare delivery is lacking in many areas, especially in poor nations, which makes it difficult to provide diagnostic services. This covers concerns with the supply chain, inadequate laboratory facilities, and skilled staff. It might be particularly difficult to access diagnostic services in rural and isolated places due to a lack of healthcare facilities and inadequate transportation infrastructure. Furthermore, HIV diagnosis rates are lower in the developing Asia-Pacific, Middle East, and African regions. These areas require a sufficient number of diagnostic facilities. Additionally, the diagnosis process needs to be explained to the majority of patients, which restricts market growth in these areas. Impact of Covid-19 on the HIV Diagnostics Market The COVID-19 pandemic has had a significant impact on the HIV diagnostics market, both in terms of challenges and opportunities. There was a decrease in HIV testing and diagnostic services during the pandemic as a result of the extensive healthcare resources being redirected to handle COVID-19. Some facilities were converted to provide COVID-19 treatment, and clinics and labs had a staffing crisis. Reduced HIV testing rates were the outcome of routine and community-based HIV testing programs being frequently halted to stop the spread of COVID-19. The adoption of telemedicine and remote healthcare services was expedited by the epidem...

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

Algeria DZ: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data was reported at 0.050 Ratio in 2022. This stayed constant from the previous number of 0.050 Ratio for 2021. Algeria DZ: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data is updated yearly, averaging 0.030 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.050 Ratio in 2022 and a record low of 0.010 Ratio in 1997. Algeria DZ: Incidence of HIV: per 1,000 Uninfected Population Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Algeria – Table DZ.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations ages 15-24 expressed per 1,000 uninfected population ages 15-24 in the year before the period.;UNAIDS estimates.;Weighted average;This is an age-disaggregated indicator for Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.020 % in 2014. This stayed constant from the previous number of 0.020 % for 2013. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.030 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.030 % in 2012 and a record low of 0.020 % in 2014. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

From 2010 to 2024, the number of new HIV infections declined globally by around 40 percent. During that period, Eastern and Southern Africa was the region where new HIV cases decreased the most, with a 56 percent decrease. This statistic illustrates the percentage changes in the number of new HIV infections worldwide from 2010 to 2024, by region.

Central African Republic CF: Incidence of HIV: per 1,000 Uninfected Population data was reported at 1.570 Ratio in 2022. This records a decrease from the previous number of 1.690 Ratio for 2021. Central African Republic CF: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 2.800 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 6.890 Ratio in 1993 and a record low of 1.570 Ratio in 2022. Central African Republic CF: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Central African Republic – Table CF.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

IT: Newly Infected with HIV: Children: Aged 0-14 data was reported at 100.000 Number in 2016. This stayed constant from the previous number of 100.000 Number for 2015. IT: Newly Infected with HIV: Children: Aged 0-14 data is updated yearly, averaging 100.000 Number from Dec 1990 (Median) to 2016, with 27 observations. The data reached an all-time high of 100.000 Number in 2016 and a record low of 100.000 Number in 2016. IT: Newly Infected with HIV: Children: Aged 0-14 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank: Health Statistics. Number of children (ages 0-14) newly infected with HIV.; ; UNAIDS estimates.; ;

HIV Antiretroviral Therapy Market Outlook

The HIV antiretroviral therapy market size was valued at USD 30 billion in 2023 and is projected to reach USD 45 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.5%. This impressive growth can be attributed to several factors, including increasing awareness about HIV, advancements in drug formulations, and the expansion of healthcare infrastructure in developing regions.

One of the primary growth drivers for the HIV antiretroviral therapy market is the increasing global prevalence of HIV/AIDS. According to the World Health Organization, approximately 37.7 million people were living with HIV worldwide in 2020, and this number is expected to rise if new infections are not curtailed. The growing awareness about the importance of early diagnosis and continuous treatment has led to an increased demand for antiretroviral drugs. Additionally, government initiatives and international funding aimed at combating the HIV epidemic have significantly boosted the market.

Another factor contributing to the market's growth is the advancement in antiretroviral drug formulations. Modern treatments are more effective, have fewer side effects, and require less frequent dosing compared to earlier drugs. Pharmaceutical companies are investing heavily in research and development to bring forth next-generation antiretroviral therapies, such as long-acting injectables and improved combination therapies. These advancements not only improve patient compliance but also enhance the quality of life for those living with HIV.

The expansion of healthcare infrastructure, particularly in developing countries, is another significant growth factor. As more regions gain access to better healthcare services and facilities, the diagnosis and treatment rates of HIV/AIDS are expected to rise. Countries in Asia Pacific and Africa are increasingly focusing on strengthening their healthcare systems, which includes improving access to antiretroviral therapy. This, coupled with international support and funding, is likely to drive market growth in these regions.

From a regional perspective, North America and Europe currently dominate the HIV antiretroviral therapy market, owing to their advanced healthcare systems, higher healthcare expenditure, and robust R&D activities. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing HIV prevalence, improving healthcare infrastructure, and rising awareness about HIV/AIDS. Latin America and the Middle East & Africa are also anticipated to register substantial growth, supported by international aid programs and government initiatives aimed at controlling the HIV epidemic.

Human Immunodeficiency Virus (HIV) Drugs have been at the forefront of medical research and development, playing a pivotal role in transforming HIV from a fatal disease to a manageable chronic condition. The development of these drugs has been marked by significant milestones, including the introduction of combination therapies that target different stages of the viral life cycle. These therapies have drastically reduced the viral load in patients, improving their quality of life and increasing life expectancy. Continuous innovation in HIV drugs is essential to address the challenges of drug resistance and to enhance treatment efficacy. The market for HIV drugs is expected to grow as new formulations and delivery methods, such as long-acting injectables, are developed to improve patient adherence and outcomes.

Drug Class Analysis

The HIV antiretroviral therapy market is segmented based on drug class, including Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry Inhibitors, and others. NRTIs form one of the cornerstone classes of antiretroviral therapy. These drugs work by incorporating themselves into the viral DNA of HIV, preventing the virus from replicating. The widespread use of NRTIs in first-line treatments and their inclusion in combination therapies have significantly bolstered their market share.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) also play a crucial role in HIV treatment. Unlike NRTIs, NNRTIs bind directly to the reverse transcriptase enzyme, inhibiting its action and thereby preventing the HIV virus from multiplying. The effectiveness

United States US: Incidence of HIV: per 1,000 Uninfected Population Aged 15-49 data was reported at 0.220 Ratio in 2018. This stayed constant from the previous number of 0.220 Ratio for 2017. United States US: Incidence of HIV: per 1,000 Uninfected Population Aged 15-49 data is updated yearly, averaging 0.250 Ratio from Dec 1990 (Median) to 2018, with 29 observations. The data reached an all-time high of 0.290 Ratio in 1990 and a record low of 0.220 Ratio in 2018. United States US: Incidence of HIV: per 1,000 Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 1,000 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted average;

UNAIDS estimated that there were some *** million adults and some *** thousand children worldwide that were newly infected with HIV in 2024. This statistic depicts the total number of annual new HIV infections among adults and children worldwide from 2000 to 2024.

As of 2023, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.7 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.4 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by Lesotho and South Africa. However, South Africa had the highest total number of new HIV infections in 2023, with around 150,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the fourth leading cause of death in Africa, accounting for around 5.6 percent of all deaths. In 2023, South Africa and Nigeria were the countries with the highest number of AIDS-related deaths worldwide with 50,000 and 45,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years and now up to 95 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 77 percent of people who are HIV positive in South Africa receiving ART, and only 31 percent in the Congo.

Italy IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.010 % in 2016. This stayed constant from the previous number of 0.010 % for 2015. Italy IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.020 % from Dec 1990 (Median) to 2016, with 27 observations. The data reached an all-time high of 0.040 % in 1995 and a record low of 0.010 % in 2016. Italy IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

Dominican Republic DO: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.040 % in 2016. This records a decrease from the previous number of 0.050 % for 2015. Dominican Republic DO: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.100 % from Dec 1990 (Median) to 2016, with 27 observations. The data reached an all-time high of 0.380 % in 1994 and a record low of 0.040 % in 2016. Dominican Republic DO: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Dominican Republic – Table DO.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

France FR: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.090 Ratio in 2022. This stayed constant from the previous number of 0.090 Ratio for 2021. France FR: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.110 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.120 Ratio in 2005 and a record low of 0.090 Ratio in 2022. France FR: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s France – Table FR.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].